Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its commercial expansion, it is evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. It is committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Company profile
Ticker
AMRN
Exchange
Website
CEO
John Thero
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
SEC CIK
Corporate docs
Subsidiaries
Amarin Pharmaceuticals Ireland Limited • Amarin Pharma, Inc. • Ester Neurosciences Limited • Amarin Switzerland GmbH • Amarin Germany GmbH • Amarin France SAS • Amarin UK Limited • Amarin Belgium, branch of Amarin Switzerland GmbH • Amarin Denmark, filial af Amarin Switzerland GmbH • Amarin Switzerland GmbH ...
AMRN stock data
Latest filings (excl ownership)
ARS
2022 FY
Annual report to shareholders
26 May 23
DEF 14A
Definitive proxy
26 May 23
PRE 14A
Preliminary proxy
9 May 23
8-K
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
3 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’connor to Company’s Board of Directors
17 Apr 23
8-K
Departure of Directors or Certain Officers
31 Mar 23
8-K
Amarin Announces Board Departures
6 Mar 23
8-K
Departure of Directors or Certain Officers
2 Mar 23
Transcripts
AMRN
Earnings call transcript
2023 Q1
3 May 23
AMRN
Earnings call transcript
2022 Q4
1 Mar 23
AMRN
Earnings call transcript
2022 Q3
27 Oct 22
AMRN
Earnings call transcript
2022 Q2
3 Aug 22
AMRN
Earnings call transcript
2022 Q1
4 May 22
AMRN
Earnings call transcript
2021 Q4
1 Mar 22
AMRN
Earnings call transcript
2021 Q3
3 Nov 21
AMRN
Earnings call transcript
2021 Q2
5 Aug 21
AMRN
Earnings call transcript
2021 Q1
29 Apr 21
AMRN
Earnings call transcript
2020 Q4
25 Feb 21
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 191.41 mm | 191.41 mm | 191.41 mm | 191.41 mm | 191.41 mm | 191.41 mm |
| Cash burn (monthly) | 8.75 mm | 2.31 mm | 5.78 mm | 8.07 mm | 2.34 mm | 7.35 mm |
| Cash used (since last report) | 17.19 mm | 4.54 mm | 11.36 mm | 15.86 mm | 4.59 mm | 14.45 mm |
| Cash remaining | 174.22 mm | 186.87 mm | 180.06 mm | 175.55 mm | 186.82 mm | 176.96 mm |
| Runway (months of cash) | 19.9 | 80.8 | 31.1 | 21.7 | 80.0 | 24.1 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 207 |
| Opened positions | 33 |
| Closed positions | 25 |
| Increased positions | 40 |
| Reduced positions | 51 |
| 13F shares | Current |
|---|---|
| Total value | 136.06 bn |
| Total shares | 112.67 mm |
| Total puts | 1.15 mm |
| Total calls | 1.41 mm |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| MS Morgan Stanley | 22.03 mm | $26.65 bn |
| Woodline Partners | 12.79 mm | $15.48 bn |
| Kynam Capital Management | 9.64 mm | $11.67 bn |
| Millennium Management | 6.92 mm | $8.55 bn |
| SCP Investment | 6.50 mm | $7.87 bn |
| DG Capital Management | 5.81 mm | $7.03 bn |
| Sarissa Capital Management | 4.81 mm | $5.82 bn |
| Two Sigma Investments | 4.17 mm | $5.04 bn |
| Ally Bridge | 3.73 mm | $4.51 bn |
| Stadium Capital Management | 3.41 mm | $4.12 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Feb 23 | Steven B Ketchum | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.03 | 7,718 | 15.67 k | 588,111 |
| 28 Feb 23 | Steven B Ketchum | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 16,333 | 0.00 | 595,829 |
| 28 Feb 23 | Steven B Ketchum | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 16,333 | 0.00 | 0 |
| 28 Feb 23 | Aaron Berg | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.03 | 7,718 | 15.67 k | 510,760 |
| 28 Feb 23 | Aaron Berg | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 16,333 | 0.00 | 518,478 |
| 28 Feb 23 | Aaron Berg | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 16,333 | 0.00 | 0 |
News
Amarin Highlights New Data Providing Potential Mechanistic Insight Into Vascepa/Vazkepa Reduction Of Cardiovascular Events
12 May 23
Amarin Corp's Return On Capital Employed Insights
9 May 23
Amarin Reports Stable Revenue, Cash Position In Q1 But Lowers FY23 Operating Expense Guidance: What's Next?
3 May 23
Recap: Amarin Corp Q1 Earnings
3 May 23
Amarin Corp Q1 Adjusted EPS $0.02 Beats $(0.03) Estimate, Sales $85.97M Beat $81.23M Estimate
3 May 23
Press releases
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
12 May 23
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
3 May 23
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
19 Apr 23
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
4 Apr 23
Amarin Announces Board Departures
6 Mar 23